A total of 17 patients with multiple osteoblastic bone metastases owing to prostatic carcinoma was treated with 2-dichloromethylene-diphosphonate, a powerful inhibitor of bone resorption. The drug was given intravenously (300 mg.) for 2 weeks and then orally (3,200 mg.) or intramuscularly (100 mg.) for 4 to 11 weeks. A definite improvement in pain, assessed by daily consumption of analgesic drugs and by an analogic scale, was observed within 10 days in 16 of the 17 patients. Four patients confined to bed rest for pain were able to walk after 2 weeks and reversal of paralysis also was noted in 1 patient. Transient changes in serum calcium (decreasing) and alkaline phosphatase (increasing) were observed in most patients. In the 3 patients in whom it was performed, repeated bone scanning showed a partial regression of pathological areas in 2 and the complete disappearance of most pathological areas in 1. Our results suggest that 2-dichloromethylene-diphosphonate may represent an important supportive treatment in patients with bone metastases owing to prostatic carcinoma, providing sustained relief of pain and regression of bone destruction without undesirable side effects.
|Data di pubblicazione:||1985|
|Titolo:||Dichloromethylene-diphosphonate in patients with prostatic carcinoma metastatic to the skeleton|
|Autore/i:||S. Adami; G. Salvagno; G. Guarrera; G. Bianchi; R. Dorizzi; S. Rosini; G. Mobilio; V. Lo Cascio|
|Codice identificativo ISI:||WOS:A1985AVJ8800023|
|Codice identificativo Scopus:||2-s2.0-0022355625|
|Citazione:||Dichloromethylene-diphosphonate in patients with prostatic carcinoma metastatic to the skeleton / S. Adami; G. Salvagno; G. Guarrera; G. Bianchi; R. Dorizzi; S. Rosini; G. Mobilio; V. Lo Cascio. - In: THE JOURNAL OF UROLOGY. - ISSN 0022-5347. - ELETTRONICO. - 134(6)(1985), pp. 1152-1154.|
|Tipologia||Articolo su rivista|
File in questo prodotto:
I documenti presenti in Iris Unimore sono rilasciati con licenza Creative Commons Attribuzione - Non commerciale - Non opere derivate 3.0 Italia, salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris